1. Van Der Heijden R, Jacobs DI, Snoeijer W, Hallard D, Verpoorte R. The Catharanthus alkaloids: Pharmacognosy and biotechnology. Curr Med Chem. 2004;11:1241-1253.

2. Boğa M, Kolak U, Topçu G, Bahadori F, Kartal M, Farnsworth NR. Two new indole alkaloids from Vinca herbacea L. Phytochemistry Let. 2011;4:399-403.

3. Almagro L, Fernández-Pérez F, Pedreño MA. Indole Alkaloids from Catharanthus roseus: Bioproduction and Their Effect on Human Health (Review).Molecules. 2015;20:2973-3000.

4. Pyuskyulev B, Ognyanov I, Panov P. Alkaloids of Vinca herbacea. Tetrahedron Let. 1967;8:4559-62.

5. Aynilian GH, Farnswor NR, Trojakek J. Alkaloids of Vinca species: Isolation and characterization of indole alkaloids from V. libanotica. J Nat Prod. 1974;37:299-308.

6. Ebrahimzadeh H, Ataei Azimi A, Noori-Dafoi MR. The distribution of indole alkaloids of C. roseus G. Don. Daru. 1996;6:17- 30.

7. Gagua N, Baghdikian B, Mabrouki F, Elias R, Vachnadze V, Bakuridze A. HPLC determination of majdine in Vinca herbacea. Nat. Prod. Commun. 2011;6:1831-1834.

8. Gulcin I, Beydemir S, Topal F, Gagua N, Bakuridze A, Bayram R. Apoptotic, antioxidant and antiradical effects of majdine and isomajdine from Vinca herbacea. J Enzyme Inhib Med Chem. 2012;27:587-94.

9. Moudi M, Go R, Yien CYS, Nazre M. Vinca Alkaloids. Int J Prev Med. 2013;4:1231-1235.

10. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-265.

11. Safarzadeh E, Sandoghchian S, Baradaran B. Herbal medicine as inducers of apoptosis in cancer treatment (Review). Adv Pharm Bull. 2014;4:421-427.

12. Park IH, Lerou PH, Zhao R, Huo H, Daley GQ. Generation of human-induced pluripotent stem cells. Nat Protoc. 2008;3:1180-1186.

13. Renaudin JP. Reversed- phase High- performance liquid chromatographic. J Chromat. 1984;291:165-174.

14. Miura Y, Hirata K, Kurano N. Formation of rose alkaloid in multiple shoot of Catharanthus roseus. Planta Med. 1987;50:18-20.

15. Moorhead PS, Nowell PC, Mellmam WJ, Battips DM, Hungerford DA. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res. 1960;20:613-616.

16. Nowell PC. Mitotic inhibition and chromosome damage by mitomycine in Human Leukocytes Cultures. Exp. Cell Res. 1964;33:445- 449.

17. Silva TL, Silva MIA, Venancio LPR, Zago CES, Moscheta VAG, Lima AVB. Simple method for culture of peripheral blood lymphocytes of Testudinidae. Genet Mol Res. 2011;10:3020-3025.

18. Ataei Azimi A, Delnavaz Hashemloian B, Ebrahimzadeh H, Majd A. High in vitro production of ant-canceric indole alkaloids from periwinkle (Catharanthus roseus) tissue culture. African J Biotechn. 2008;7:2834-2839.

19. Jean-Decoster C, Brichese L, Barret J, Tollon Y, Kruczynski A, Hill B. Vinflunine, a new Vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anti-Cancer Drugs. 1999;10:537-543.

20. Hadfield JA, Lawrence NJ, Mcgown AT. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Med Res Rev. 1998;18:259-296.

21. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA. Structural basis for the regulation of tubulin by vinblastine. Nature. 2005;435:519-522.

22. Daly EM, Taylor RE. Entropy and enthalpy in the activity of tubulin-based antimitotic agents. Curr Chem Bio. 2009;l3:47–59.

23. Sertel S, Fu Y, Zu Y, Rebacz B, Konkimalla B, Plinkert PK. Molecular docking and pharmacogenomics of Vinca alkaloid and their monomeric precursor, vindoline and catharanthine. Biochem Pharmacol. 2011;81:723-735.

24. Coderch C, Morreale A, Gago F. Tubulin-based structure-affinity relationship for antimitotic Vinca alkaloid. Anticancer Agents Med Chem. 2012;12:219-225.

25. Tsvetkov FO, Kulikova AA, Devred F, Zernii E, Lafitte D, Makarov AA. Thermodynamics of calmodulin and tubulin binding to the Vinca-alkaloid vinorelbine. Mol Biol. 2011;45:697-702.

26. Barbier P, Tsvetkov PO, Breuzard G, Devred F. Deciphering the molecular mechanism of anti-tubulin plant derived drugs. Phytochem Rev. 2013;13:157-169.